- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06910813
DFT383 lasten osallistujilla, joilla on nefropaattinen kystinoosi (CYStem)
Avoin, monikeskus, vaiheen I/II tutkimus DFT383: n turvallisuuden, siedettävyyden ja tehokkuuden arvioimiseksi lasten osallistujilla, joilla on nefropaattinen kystinoosi
An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.
The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.
This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.
The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.
Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.
The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.
Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.
Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Novartis Pharmaceuticals
- Puhelinnumero: 1-888-669-6682
- Sähköposti: novartis.email@novartis.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Novartis Pharmaceuticals
Opiskelupaikat
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85016
- Rekrytointi
- Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
-
Ottaa yhteyttä:
- Erica Sieber
- Puhelinnumero: 602-933-0171
- Sähköposti: esieber@phoenixchildrens.com
-
Päätutkija:
- Shanna White
-
-
California
-
San Diego, California, Yhdysvallat, 92123
- Rekrytointi
- University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
-
Ottaa yhteyttä:
- Mieko Pretlow
- Puhelinnumero: Ext 226010 858-966-1700
- Sähköposti: mpretlow@rchsd.org
-
Päätutkija:
- Nadine Benador nbenador@health.ucsd.edu
-
Stanford, California, Yhdysvallat, 94305
- Rekrytointi
- Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
-
Päätutkija:
- Alice Bertaina
-
Ottaa yhteyttä:
- Research Nurse
- Puhelinnumero: (650) 725-9032
- Sähköposti: scgt_clinical_trials_office@lists.stanford.edu
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
-
Päätutkija:
- Laurence (Larry) Greenbaum
-
Ottaa yhteyttä:
- Laurence (Larry) Greenbaum
- Puhelinnumero: 404-712-6374
- Sähköposti: lgreen6@emory.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- Children's Hospital of Philadelphia (Recruiting Cohort 0)
-
Ottaa yhteyttä:
- Melissa Cadnapaphornchai
- Puhelinnumero: 215-590-2449
-
Päätutkija:
- Melissa Cadnapaphornchai
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Rekrytointi
- Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
-
Ottaa yhteyttä:
- Ewa Elenberg
- Puhelinnumero: 832-824-3800
- Sähköposti: Email_elenberg@bcm.edu
-
Päätutkija:
- Ewa Elenberg
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Key Inclusion Criteria:
Participants eligible for inclusion in this study must meet all the following criteria:
- Informed consent in writing from parent(s) or legal guardian(s) must be provided
- 2 to 5 years of age (including 5 years and 364 days old) at Screening
- Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
- Oral cysteamine therapy for at least 6 months
- Historic clinical diagnosis of nephropathic cystinosis
- Laboratory evidence of of renal fanconi syndrome (RFS)
- Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
- Received all age-appropriate vaccinations
Key exclusion Criteria for Cohort 1 and 0
- A history of kidney transplantation
- A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
- History of malignancy
- A severe or uncontrolled medical disorder
- Major surgery within 90 days
Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:
1. Indomethacin within 2 weeks prior to Screening
Other protocol-defined inclusion/exclusion criteria may apply.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Cohort 1 (DFT383)
Treatment with DFT383 |
DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy. |
|
Ei väliintuloa: Cohort 0 (SoC)
No study treatment, will continue with standard of care (cysteamine). |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Core Phase - Incidence of adverse events (Cohort 1)
Aikaikkuna: Up to 32 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 32 months
|
|
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Aikaikkuna: 42 days post DFT infusion
|
Hematological reconstitution by Day 42 post-DFT383 infusion |
42 days post DFT infusion
|
|
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Aikaikkuna: Up to 32 months
|
Proportion of participants with reversal of renal Fanconi syndrome (RFS) |
Up to 32 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Core Phase - Number of participants independent from cysteamine
Aikaikkuna: up to 24 months
|
Independence from oral and ophthalmic cysteamine |
up to 24 months
|
|
Core Phase - Health-related quality of life (HRQOL)
Aikaikkuna: Up to 32 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 32 months
|
|
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Aikaikkuna: Up to 24 months
|
Time from infusion to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Aikaikkuna: Up to 24 months
|
Time from screening to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Duration of reversal of RFS
Aikaikkuna: Up to 24 months
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Aikaikkuna: Up to 27 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 27 months
|
|
Core Phase - Change from baseline on urine amino acids
Aikaikkuna: Up to 27 months
|
Change from baseline on urine amino acids |
Up to 27 months
|
|
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Aikaikkuna: Up to 27 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Aikaikkuna: Up to 27 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Aikaikkuna: Up to 27 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 27 months
|
|
Core Phase - Number of participants with improvement of proximal tubular function
Aikaikkuna: Up to 27 months
|
Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization. |
Up to 27 months
|
|
Core Phase - Corneal cystine crystal content
Aikaikkuna: Up to 27 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 27 months
|
|
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Aikaikkuna: Up to 27 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 27 months
|
|
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Aikaikkuna: Up to 27 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 27 months
|
|
Core Phase - Number of participants with malignancy (Cohort 1)
Aikaikkuna: Up to 27 months
|
Number of participants with malignancy |
Up to 27 months
|
|
Core Phase - Time to hematological reconstitution (Cohort 1)
Aikaikkuna: Up to 24 months
|
Time to hematological reconstitution |
Up to 24 months
|
|
Core Phase - Time to platelet engraftment (Cohort 1)
Aikaikkuna: Up to 24 months
|
Time to platelet engraftment |
Up to 24 months
|
|
Core Phase - Incidence of Adverse Events (Cohort 0)
Aikaikkuna: up to 24 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
up to 24 months
|
|
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Aikaikkuna: Up to 15 years and 8 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 15 years and 8 months
|
|
Extension Phase - Number of participants with malignancy (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Number of participants with malignancy |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Change from baseline on urine amino acids |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Duration of reversal of RFS (Cohort 1)
Aikaikkuna: Up to 15 years
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 15 years
|
|
Extension Phase - Number of participants with kidney failure (Cohort 1)
Aikaikkuna: Up to 15 years
|
Number of participants with kidney failure |
Up to 15 years
|
|
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Aikaikkuna: Up to 15 years
|
Independence from oral and ophthalmic cysteamine |
Up to 15 years
|
|
Extension Phase - Corneal cystine crystal content (Cohort 1)
Aikaikkuna: Up to 15 years and 3 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 15 years and 3 months
|
|
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Aikaikkuna: Up to 15 years and 8 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 15 years and 8 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Miesten urogenitaaliset sairaudet
- Munuaissairaudet
- Urologiset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Aineenvaihdunta, synnynnäiset virheet
- Geneettiset sairaudet, synnynnäiset
- Metaboliset sairaudet
- Munuaistiehyen kulku, synnynnäiset virheet
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Ravitsemukselliset ja aineenvaihduntataudit
- Kystinoosi
- Fanconin oireyhtymä
- Lysosomaaliset varastointitaudit
Muut tutkimustunnusnumerot
- CDFT383A12101
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .